-
This special feature will summarize FDA position statements pertaining to mesh use in obstetrics and gynecology....
-
The association between oral contraceptive use and ovarian or breast cancer in BRCA1 or BRCA2 mutation carriers are qualitatively similar to associations reported in the general population.
-
In a Phase 3, randomized clinical trial of primary systemic therapy for patients with early, locally advanced breast cancer, the addition of capecitabine to each of six 3-weekly cycles of epirubicin-docetaxel resulted in a 1.64 fold increase in the possibility of primary tumor pathologic complete response.
-
In a Phase 2 trial, Ludwig and colleagues present data on 79 patients with relapsed or refractory myeloma who were treated with bendamustine in combination with bortezomib and dexamethasone.
-
Patients with progressive advanced esophagogastric adenocarcinoma treated with docetaxel in addition to active symptom control (ASC) survived 44% longer than those who received ASC alone.
-
In a Phase 2 study, Ahmadi and colleagues demonstrate reasonably high response rates in rituximab-resistant indolent lymphoma patients sequentially treated with lenalidomide/dexamethasone (Part 1; 2 monthly cycles) followed by lenalidomide/dexamethasone + weekly rituximab (Part 2; 3 monthly cycles).
-
Women presenting for emergency contraception were offered a copper IUD or Plan B. Those who chose an IUD had a lower cumulative risk of unintended pregnancy at 1 year.
-
Long-term complications, particularly secondary cancers, were significantly more common in patients receiving whole pelvic radiation (vs brachytherapy alone) for early-stage endometrial cancer.
-
In this large, retrospective cohort study, women with a history of bariatric surgery were at a small increased risk of both spontaneous and medically indicated preterm birth and small for gestational age births.
-
Hopefully, as multi-institution, randomized trials are developed for second-line treatment of pancreatic cancer, CA19-9 levels will be included both pre- and post-first cycle treatment and responses compared with the established RECIST criteria.